CancerFax

Can advanced-stage cancer be cured? Check the latest developments

Susan HauWritten by Susan HauMedically ReviewedUpdated February 24, 20235 min read
Can advanced-stage cancer be cured? Check the latest developments
In this article
  1. Evolution of Targeted Lung Cancer Therapy
  2. Global and National Cancer Statistics
  3. Innovations in Surgical Cancer Management
  4. Breakthroughs in Medical and Cellular Therapies
  5. Making the treatment accessible and affordable
  6. How CancerFax Helps

Evolution of Targeted Lung Cancer Therapy

Feb 2023:

Three to five years ago, it would have been impossible to imagine a Stage 3 lung cancer patient living a normal life. However, contemporary targeted cancer therapies have made the impossible a reality. A 35-year-old man with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) became asymptomatic after three months of treatment with the targeted drug lorlatinib. This feat is just one of the numerous advancements in cancer treatment over the past five years.

Global and National Cancer Statistics

Cancer is currently regarded as one of the most infamous noncommunicable diseases worldwide. It is currently the third leading cause of death, but by 2030, it is projected to be the leading killer. According to the International Agency for Research on Cancer (IARC), the global cancer burden has increased to 19.3 million cases and will result in 10 million cancer-related deaths by 2020. The population is projected to increase by 47%, or to 28.4 million, by 2040. Statistically speaking, according to IARC findings, one in five people develops cancer during their lifetime. In India, the proportion is marginally better, at one in nine individuals. But still unsettling.

Innovations in Surgical Cancer Management

Surgical procedures, radiation therapy, chemotherapy, targeted therapy, hormonal therapy, cancer vaccines, and immunotherapy are currently available as cancer treatments. Again, these can be classified as the surgical and medical management of the disease.

There have been numerous innovations and breakthroughs in both fields over the past five years.

Surgical management: Robotic surgery and keyhole surgery have emerged as major advances in the treatment of cancer. In India, there has been a significant increase in oncorobotics and robotic oncology surgery over the past two years. India has become one of the leading countries in the use of robotics for cancer treatment, particularly in the fields of gynecological and urological cancers, due to the adoption of robotic surgery by prominent institutions. Reduced functional loss and mutilation of patients’ bodies has resulted in a significant reduction in recovery time. This has not only increased surgical precision but also decreased recovery time significantly.

Breakthroughs in Medical and Cellular Therapies

Medical management—About a decade ago, chemotherapy was the only known cancer treatment, but in the last 5 to 7 years, there have been significant advances in radiation, immunotherapy, and targeted therapy.

The use of advanced radiotherapy techniques in India, such as intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT), has significantly improved cancer treatment. The process damages DNA and inhibits the division and growth of cancer cells. Immunotherapy, which involves a more targeted and concentrated treatment of cancerous cells, has helped even Stage 4 cancer patients live longer and with a higher quality of life. It is known that these therapies are effective against over 30 types of cancer, including breast cancer, lung cancer, prostate cancer, and even genetic cancers. Targeted therapies are small-molecule drugs that have been genetically engineered to inhibit targets on cancer cells. They are administered orally and are effective against chronic leukemias, myelomas, lung cancer, and breast cancer. On multiple occasions, these medications have not only controlled the disease but also cured it.

In terms of advancements, cellular therapies and living drugs are gaining prominence. On the premise that the body’s own immune cells can recognise and destroy cancerous cells, immune cells are extracted, multiplied, and genetically modified in a controlled environment before being used as a treatment. Innovations in this field, known as Chimeric Antigen Receptor T-cell (CAR-T) therapy, are anticipated to alter the dynamics of cancer treatment. Under the Make in India initiative, such drugs are currently being developed and tested at Tata Memorial Hospital and IIT Mumbai.

Making the treatment accessible and affordable

The fact that India is producing innovative CAR-T drugs is a source of immense national pride. In addition, they will help reduce the cost of treatment by a tenth or more. Indeed, affordability and accessibility continue to be two of the greatest obstacles cancer patients face today. In light of the fact that 70 to 80 percent of our population lacks access to diagnostic testing and targeted therapies, initiatives such as these provide cause for optimism.

Obviously, the process of discovering new drugs is expensive and difficult. To create a conducive and supportive environment, the country should incentivize innovation and promote collaboration with leading research institutions. In addition, we need a robust regulatory framework, more government programs like the Pradhan Mantri Jan Arogya Yojana (PMJAY), and a greater number of new cancer hospitals and centers in Tier-2 and even Tier-3 cities. This will make cancer treatment more affordable and widely available, allowing us to win the war against this disease.

How CancerFax Helps

CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.

description
Medical Record Review

We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.

verified_user
Eligibility Coordination

We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.

hub
Hospital Communication

We support appointment coordination, document submission, translation, and direct communication with international departments.

flight
Travel & Admission Support

For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.

explore
Treatment & Trial Navigation

If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.

support_agent
End-to-end Coordination

From inquiry through to follow-up, our coordinators provide a single point of contact for the family.

CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

Susan Hau

About Susan Hau

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…

✓ Reviewed for medical accuracy by the CancerFax review panel.

Medical Disclaimer

This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.

Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.